157 related articles for article (PubMed ID: 23739952)
1. Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats.
Yamaura S; Fukao M; Ishida K; Taguchi M; Hashimoto Y
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):53-9. PubMed ID: 23739952
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes.
Ishida K; Taira S; Morishita H; Kayano Y; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 Jun; 31(6):1297-300. PubMed ID: 18520073
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory and stimulative effects of amiodarone on metabolism of carvedilol in human liver microsomes.
Horiuchi I; Kato Y; Nakamura A; Ishida K; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2010; 33(4):717-20. PubMed ID: 20410613
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes.
Hanioka N; Tanaka S; Moriguchi Y; Narimatsu S
Pharmacology; 2012; 90(3-4):117-24. PubMed ID: 22814440
[TBL] [Abstract][Full Text] [Related]
5. Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes.
Takekuma Y; Yagisawa K; Sugawara M
Biol Pharm Bull; 2012; 35(2):151-63. PubMed ID: 22293344
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Enhancement of Carvedilol Glucuronidation by Amiodarone-Mediated Altered Protein Binding in Incubation Mixture of Human Liver Microsomes with Bovine Serum Albumin.
Sekimoto M; Takamori T; Nakamura S; Taguchi M
Biol Pharm Bull; 2016; 39(8):1359-63. PubMed ID: 27476943
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective glucuronidation of carvedilol by Chinese liver microsomes.
You LY; Yu CN; Xie SG; Chen SQ; Zeng S
J Zhejiang Univ Sci B; 2007 Oct; 8(10):756-64. PubMed ID: 17910120
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
Nardotto GHB; Lanchote VL; Coelho EB; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S108-S115. PubMed ID: 28522373
[TBL] [Abstract][Full Text] [Related]
9. Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics.
Stahl E; Baumgartner U; Henke D; Schölmerich J; Mutschler E; Spahn-Langguth H
Chirality; 1993; 5(1):1-7. PubMed ID: 8095396
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
Horiuchi I; Nozawa T; Fujii N; Inoue H; Honda M; Shimizu T; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529
[TBL] [Abstract][Full Text] [Related]
11. Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study.
Nardotto GHB; Coelho EB; Marques MP; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():173-180. PubMed ID: 26927877
[TBL] [Abstract][Full Text] [Related]
12. Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.
Nardotto GHB; Coelho EB; Paiva CE; Lanchote VL
J Clin Pharmacol; 2017 Jun; 57(6):760-769. PubMed ID: 28114735
[TBL] [Abstract][Full Text] [Related]
13. A validated enantioselective LC-MS/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma: application to a clinical pharmacokinetic study.
Furlong MT; He B; Mylott W; Zhao S; Mariannino T; Shen J; Stouffer B
J Pharm Biomed Anal; 2012 Nov; 70():574-9. PubMed ID: 22709607
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of carvedilol in dogs, rats, and mice.
Schaefer WH; Politowski J; Hwang B; Dixon F; Goalwin A; Gutzait L; Anderson K; DeBrosse C; Bean M; Rhodes GR
Drug Metab Dispos; 1998 Oct; 26(10):958-69. PubMed ID: 9763400
[TBL] [Abstract][Full Text] [Related]
15. Saturable enantioselective first-pass effect for carvedilol after high oral racemate doses in rats.
Stahl E; Henke D; Mutschler E; Spahn-Langguth H
Arch Pharm (Weinheim); 1993 Mar; 326(3):123-5. PubMed ID: 8097624
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound.
Neugebauer G; Akpan W; Kaufmann B; Reiff K
Eur J Clin Pharmacol; 1990; 38 Suppl 2():S108-11. PubMed ID: 1974498
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in beta-naphthoflavone-treated Caco-2 cells.
Ishida K; Taguchi M; Akao T; Hashimoto Y
Biol Pharm Bull; 2009 Mar; 32(3):513-6. PubMed ID: 19252307
[TBL] [Abstract][Full Text] [Related]
18. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
[TBL] [Abstract][Full Text] [Related]
19. Studies on formulation development of mouth dissolving tablets of Carvedilol.
Pokharkar V; Dhar S; Mandpe L
Hindustan Antibiot Bull; 2007 Feb-2008 Nov; 49-50(1-4):21-8. PubMed ID: 19957540
[TBL] [Abstract][Full Text] [Related]
20. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol.
Oldham HG; Clarke SE
Drug Metab Dispos; 1997 Aug; 25(8):970-7. PubMed ID: 9280405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
